Epstein Secrets

ress-News, "The information was contained in documents related to a detention hearing for Alexander Hillel Treisman, held in U.S. District Court in Durham. A magistrate, in an order signed Oct. 8, ordered Treisman to remain in custody. An officer with the U.S. Marshal's Service and the Joint Terrorism

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

press-News, "The information was contained in documents related to a detention hearing for Alexander Hillel Treisman, held in U.S. District Court in Durham. A magistrate, in an order signed Oct. 8, ordered Treisman to remain in custody. An officer with the U.S. Marshal's Service and the Joint Terrorism

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

ress-News, "The information was contained in documents related to a detention hearing for Alexander Hillel Treisman, held in U.S. District Court in Durham. A magistrate, in an order signed Oct. 8, ordered Treisman to remain in custody. An officer with the U.S. Marshal's Service and the Joint Terrorism

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug